Drug Type Personalized antigen vaccine |
Synonyms- |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Inactive Indication- |
Originator Organization Nouscom AGStartup |
Active Organization Nouscom AGStartup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Melanoma, Cutaneous Malignant | Phase 1 | BE | Nouscom AGStartup | 11 Jun 2021 |
Melanoma, Cutaneous Malignant | Phase 1 | ES | Nouscom AGStartup | 11 Jun 2021 |
Melanoma, Cutaneous Malignant | Phase 1 | GB | Nouscom AGStartup | 11 Jun 2021 |
Non-Small Cell Lung Cancer | Phase 1 | BE | Nouscom AGStartup | 11 Jun 2021 |
Non-Small Cell Lung Cancer | Phase 1 | ES | Nouscom AGStartup | 11 Jun 2021 |
Non-Small Cell Lung Cancer | Phase 1 | GB | Nouscom AGStartup | 11 Jun 2021 |
Unresectable Melanoma | Phase 1 | BE | Nouscom AGStartup | 11 Jun 2021 |
Unresectable Melanoma | Phase 1 | ES | Nouscom AGStartup | 11 Jun 2021 |
Unresectable Melanoma | Phase 1 | GB | Nouscom AGStartup | 11 Jun 2021 |